Trial
NCT00498914
Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Astellas Pharma Inc
Collaborators
—
Condition
Lymphoma, Large-Cell, Diffuse
Intervention
YM155
Why stopped
Futility boundary at interim analysis not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-04